OTLK

Outlook is a single-product biopharma whose entire investment case rests on ONS-5010/LYTENAVA, an ophthalmic bevacizumab for wet AMD. The EU/UK approvals are real and the addressable market the company cites is large (~$3.6B Europe, ~$8.5B US anti-VEGF retina), but the FY2025 numbers show a company that has barely begun to monetize it: revenue of just $1.41M against a -$67.1M operating loss and a -$51.8M operating cash outflow. Gross profit is a rounding error ($57.2K, a 4.0% gross margin), so the June 2025 Germany/UK direct launch is not yet generating the scale to matter. At a $93M market cap this trades at a 65.8x price-to-sales multiple — a valuation that prices in a successful commercial ramp and, implicitly, US approval that has not happened.

The balance sheet is the disqualifier. Stockholders' equity is negative at -$32.2M (liabilities/equity of -1.58x), and cash & equivalents fell 45.9% to $8.08M — roughly two months of the FY2025 operating burn. Current liabilities of $45.8M swamp current assets of $17.4M, a working-capital hole that all but guarantees further financing. The company already diluted holders massively: shares outstanding rose 157.4% year-over-year to 64.1M, and the -$606M accumulated deficit shows how long this cash-consumption pattern has run. The MD&A's own emphasis on 'substantial capital requirements' underscores that survival depends on continuous capital raises on whatever terms the market offers.